Find a Clinical Trial

With over 70 clinical trials across the globe, Karyopharm is committed to developing novel treatment options to patients in need. Search here for ongoing clinical trials evaluating Karyopharm’s investigational medicines.

Karyopharm-Sponsored Trials Investigator-Sponsored Trials

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

This is a prospective, multicenter, double-blind, placebo-controlled, randomized Phase 3 study. The purpose of the study is to obtain evidence of efficacy for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized in a 2:1 manner to maintenance therapy with 80 milligram (mg) with selinexor once weekly (QW) or placebo until progression.
Primary Condition
Endometrial Cancer
Sponsor
Karyopharm Therapeutics Inc
Status
Recruiting
Drug
Selinexor
Phase
Phase 3
Age Group
18 Years+
Primary Condition
Endometrial Cancer